The Pfizer-BioNTech Covid-19 antibody, sold under the brand name ‘Comirnaty’, may need a third dose to work more vigorously against the original strain of the coronavirus infection (Covid-19), news agencies reported on Friday morning, citing a statement from the manufacturers from a day ago. The third Covid-19 shot is also anticipated to provide better shielding against the Beta variant, first notified in South Africa, and the Delta variant, detected in India, as per provisional data from an ongoing examination into the vaccine.
Pfizer and BioNTech asserted on Thursday that they would seek regulatory authorisation for the third dose of their Covid-19 vaccine, considering the interim examine data which marked that a third dose can enhance antibody levels five to 10 times higher against the said variants of the coronavirus analyzed to the first two doses alone. This will, in effect, supply better shielding than the current practice of monitoring two shots, the statement read.
The evolution comes after the vaccine was detailed to be ineffectual against the Delta variant of the SARS-CoV-2 virus. A study, released in the journal ‘Nature’, showed that a single shot of the Pfizer-BioNTech immunization, or even the AstraZeneca shot for that matter, “barely” activates any neutralising antibodies against the Delta Covid-19 strain.
The Pfizer-BioNTech Covid-19 immunization was reportedly reducing in efficacy after six months, the Israeli government said prior to this week. According to Bloomberg, a report from Israel’s health ministry said the Pfizer Covid-19 vaccine covers 64% of the country’s people against the virus between June 6 and early July, down from the earlier 94%.
This droop has been seen amid the emergence and rise in cases of Delta variant in the nation, the data disclosed. Commenting on the matter, Pfizer-BioNTech said that the third dose may be required within six to 12 months after full vaccination for complete shielding.
In light of these discoveries, Pfizer-BioNTech declared that the pharma firms are working on a Delta-specific vaccine, the initial batch of which has already been created at BioNTech’s facility in Mainz, Germany.
Thus, more studies are required in this field and the companies expects the clinical trials to start in August, subject to regulatory authorization.
“The firms expect to release more definitive information soon as well as in a peer-reviewed journal and scheme to submit the data to the FDA (Food and Drug Administration), EMA (European Medicines Agency) and other regulatory bodies in the coming weeks,” the statement said.